Combination index analysis of a regimen of bortezomib and OSI-906 in drug-naive and BR myeloma models
| . | OSI-906, μM . | Bortezomib, nM . | ||
|---|---|---|---|---|
| 3 . | 6 . | 12 . | ||
| ANBL-6.wt | ||||
| 0.05 | 0.45 | 0.52 | 1.0 | |
| 0.1 | 0.57 | 0.55 | 0.97 | |
| 0.5 | 0.46 | 0.56 | 1.1 | |
| 1 | 0.41 | 0.51 | 1.1 | |
| ANBL-6.BR | ||||
| 0.05 | 0.26 | 0.43 | 0.61 | |
| 0.1 | 0.24 | 0.42 | 0.6 | |
| 0.5 | 0.23 | 0.4 | 0.59 | |
| 1 | 0.21 | 0.39 | 0.56 | |
| 8226.wt | ||||
| 0.05 | 0.38 | 0.44 | 0.62 | |
| 0.1 | 0.55 | 0.5 | 0.68 | |
| 0.5 | 0.35 | 0.34 | 0.58 | |
| 1 | 0.46 | 0.42 | 0.66 | |
| 8226.BR | ||||
| 0.05 | 1.0 | 0.49 | 0.63 | |
| 0.1 | 1.3 | 0.63 | 0.63 | |
| 0.5 | 1.2 | 0.84 | 0.5 | |
| 1 | 0.36 | 0.69 | 0.48 | |
| . | OSI-906, μM . | Bortezomib, nM . | ||
|---|---|---|---|---|
| 3 . | 6 . | 12 . | ||
| ANBL-6.wt | ||||
| 0.05 | 0.45 | 0.52 | 1.0 | |
| 0.1 | 0.57 | 0.55 | 0.97 | |
| 0.5 | 0.46 | 0.56 | 1.1 | |
| 1 | 0.41 | 0.51 | 1.1 | |
| ANBL-6.BR | ||||
| 0.05 | 0.26 | 0.43 | 0.61 | |
| 0.1 | 0.24 | 0.42 | 0.6 | |
| 0.5 | 0.23 | 0.4 | 0.59 | |
| 1 | 0.21 | 0.39 | 0.56 | |
| 8226.wt | ||||
| 0.05 | 0.38 | 0.44 | 0.62 | |
| 0.1 | 0.55 | 0.5 | 0.68 | |
| 0.5 | 0.35 | 0.34 | 0.58 | |
| 1 | 0.46 | 0.42 | 0.66 | |
| 8226.BR | ||||
| 0.05 | 1.0 | 0.49 | 0.63 | |
| 0.1 | 1.3 | 0.63 | 0.63 | |
| 0.5 | 1.2 | 0.84 | 0.5 | |
| 1 | 0.36 | 0.69 | 0.48 | |
BR indicates bortezomib resistant; and wt, wild-type.
The combination index (CI) is a quantitative measure of the degree of drug interaction, with a CI < 1 indicating synergy, a CI = 1 indicating additive effects, and a CI > 1 indicating antagonism.